181 related articles for article (PubMed ID: 36951157)
1. Updated insights on cardiac risks of CD19-directed chimeric antigen receptor T-cell therapy: a pharmacovigilance study.
Zhai Y; Hu F; Zhu B; Xu J; Guo X; Shi W; Zhou X; Zheng Y; Xu X; Ye X; He J; Xu F
Immunotherapy; 2023 Apr; 15(6):443-456. PubMed ID: 36951157
[TBL] [Abstract][Full Text] [Related]
2. Chimeric antigen receptor T-cell therapy-induced nervous system toxicity: a real-world study based on the FDA Adverse Event Reporting System database.
Ren X; Zhang G; Li G; Wang Y
BMC Cancer; 2024 Jan; 24(1):10. PubMed ID: 38166723
[TBL] [Abstract][Full Text] [Related]
3. Adverse Cardiovascular and Pulmonary Events Associated With Chimeric Antigen Receptor T-Cell Therapy.
Goldman A; Maor E; Bomze D; Liu JE; Herrmann J; Fein J; Steingart RM; Mahmood SS; Schaffer WL; Perales MA; Shouval R
J Am Coll Cardiol; 2021 Nov; 78(18):1800-1813. PubMed ID: 34711339
[TBL] [Abstract][Full Text] [Related]
4. Safety profile of chimeric antigen receptor T-cell immunotherapies (CAR-T) in clinical practice.
Bonaldo G; Montanaro N; AlbertoVaccheri ; Motola D
Eur J Clin Pharmacol; 2021 Aug; 77(8):1225-1234. PubMed ID: 33608749
[TBL] [Abstract][Full Text] [Related]
5. Ocular toxicities in chimeric antigen receptor T-cell therapy: a real-world study leveraging FAERS database.
Zhao N; Hu F; Zhai Y; Ye X; Ruan Y; Liu Z; Wang Z; Shen W; Yuan L
Immunotherapy; 2024 Feb; 16(3):161-172. PubMed ID: 38126138
[TBL] [Abstract][Full Text] [Related]
6. Chimeric antigen receptor T-cells safety: A pharmacovigilance and meta-analysis study.
Dolladille C; Ederhy S; Ezine E; Choquet S; Nguyen LS; Alexandre J; Moslehi JJ; Dechartres A; Salem JE
Am J Hematol; 2021 Sep; 96(9):1101-1111. PubMed ID: 34057232
[TBL] [Abstract][Full Text] [Related]
7. Post-Marketing Surveillance of CAR-T-Cell Therapies: Analysis of the FDA Adverse Event Reporting System (FAERS) Database.
Fusaroli M; Isgrò V; Cutroneo PM; Ferrajolo C; Cirillo V; Del Bufalo F; Raschi E; Poluzzi E; Trifirò G
Drug Saf; 2022 Aug; 45(8):891-908. PubMed ID: 35829913
[TBL] [Abstract][Full Text] [Related]
8. Cardiotoxic profiles of CAR-T therapy and bispecific T-cell engagers in hematological cancers.
Karthikeyan B; Sunder SS; Puzanov I; Olejniczak SH; Pokharel S; Sharma UC
Commun Med (Lond); 2024 Jun; 4(1):116. PubMed ID: 38871977
[TBL] [Abstract][Full Text] [Related]
9. Impact of
Shouval R; Alarcon Tomas A; Fein JA; Flynn JR; Markovits E; Mayer S; Olaide Afuye A; Alperovich A; Anagnostou T; Besser MJ; Batlevi CL; Dahi PB; Devlin SM; Fingrut WB; Giralt SA; Lin RJ; Markel G; Salles G; Sauter CS; Scordo M; Shah GL; Shah N; Scherz-Shouval R; van den Brink M; Perales MA; Palomba ML
J Clin Oncol; 2022 Feb; 40(4):369-381. PubMed ID: 34860572
[TBL] [Abstract][Full Text] [Related]
10. Cardiotoxicity of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: Pathophysiology, Clinical Implications, and Echocardiographic Assessment.
Nenna A; Carpenito M; Chello C; Nappi P; Annibali O; Vincenzi B; Grigioni F; Chello M; Nappi F
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897819
[TBL] [Abstract][Full Text] [Related]
11. Chimeric antigen receptor T-cell immunotherapies adverse events reported to FAERS database: focus on cytopenias.
Gomez-Lumbreras A; Mercadal Vilchez S; Villa-Zapata L; Malone DC; Couriel DR
Leuk Lymphoma; 2023 Dec; 64(13):2071-2080. PubMed ID: 37708442
[TBL] [Abstract][Full Text] [Related]
12. Ocular adverse events following CAR-T cell therapy: A pharmacovigilance study and systematic review.
Frey C; Cherniawsky H; Etminan M
Eur J Haematol; 2024 Jul; 113(1):66-71. PubMed ID: 38549191
[TBL] [Abstract][Full Text] [Related]
13. Chimeric Antigen Receptor-Engineered T Cell Therapy in Lymphoma.
Strati P; Neelapu SS
Curr Oncol Rep; 2019 Mar; 21(5):38. PubMed ID: 30919158
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness of Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed or Refractory Large B Cell Lymphoma: No Impact of Site of Care.
Cummings Joyner AK; Snider JT; Wade SW; Wang ST; Buessing MG; Johnson S; Gergis U
Adv Ther; 2022 Aug; 39(8):3560-3577. PubMed ID: 35689726
[TBL] [Abstract][Full Text] [Related]
15. Chimeric Antigen Receptor T-Cell Therapies for Aggressive B-Cell Lymphomas: Current and Future State of the Art.
Abramson JS; Lunning M; Palomba ML
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():446-453. PubMed ID: 31099671
[TBL] [Abstract][Full Text] [Related]
16. Systematic Review and Meta-analysis of CD19-Specific CAR-T Cell Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia in the Pediatric and Young Adult Population: Safety and Efficacy Outcomes.
Aamir S; Anwar MY; Khalid F; Khan SI; Ali MA; Khattak ZE
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e334-e347. PubMed ID: 33573914
[TBL] [Abstract][Full Text] [Related]
17. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.
Schultz L
Front Immunol; 2020; 11():1985. PubMed ID: 32849662
[TBL] [Abstract][Full Text] [Related]
18. Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy.
Cappell KM; Sherry RM; Yang JC; Goff SL; Vanasse DA; McIntyre L; Rosenberg SA; Kochenderfer JN
J Clin Oncol; 2020 Nov; 38(32):3805-3815. PubMed ID: 33021872
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular Events Associated with Chimeric Antigen Receptor T Cell Therapy: Cross-Sectional FDA Adverse Events Reporting System Analysis.
Guha A; Addison D; Jain P; Gutierrez JM; Ghosh A; Roddie C; de Lima M; Al-Kindi S; Oliveira GH
Biol Blood Marrow Transplant; 2020 Dec; 26(12):2211-2216. PubMed ID: 32966880
[TBL] [Abstract][Full Text] [Related]
20. Toxicity and efficacy of chimeric antigen receptor T-cell therapy in patients with diffuse large B-cell lymphoma above the age of 70 years compared to younger patients - a matched control multicenter cohort study.
Ram R; Grisariu S; Shargian-Alon L; Amit O; Bar-On Y; Stepensky P; Yeshurun M; Avni B; Hagin D; Perry C; Gurion R; Sarid N; Herishanu Y; Gold R; Glait-Santar C; Kay S; Avivi I
Haematologica; 2022 May; 107(5):1111-1118. PubMed ID: 34233446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]